Skip to main content
Equibles
UTHR logo

UTHR · UNITED THERAPEUTICS Corp

Track UTHR — free

Use UTHR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about UTHR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$529.41 +11.14 (+2.15%) At close · Aug 19
Market Cap
$22.23B
Shares
42.89M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$518.27 Open$510.42 Day$508.56–519.21 52W close$304.76–596.76 Avg vol 30d468K Short int2.3M · 5.4% float · 5.5d Short vol61% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Oct 25, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Sell Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −0%
      below
      Price vs 50-day avg −3%
      below
      RSI (14) 47
      neutral
      MACD trend Negative
      52-week position 73%
      mid-range
      Momentum
      relative strength
      Weak
      1-month return −3%
      trailing
      6-month return −3%
      trailing
      YTD return +6%
      this year
      Relative strength −14%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $535 › 200d $520 — 50d above 200d
      Institutional flow Accumulating
      +4% holders QoQ · +115 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      5.42% of float · ▲ +11.2% MoM · 5.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      871 holders — near 3-yr high, broad support
      Squeeze score 69
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +2%
      Y/Y
      Gross margin 189%
      expanding
      EPS growth +13%
      Y/Y
      Free cash flow $1.0B
      Valuation P/E 18.6
      below peers
      Buyback $500.0M
      remaining
      Balance sheet $1.6B
      net cash
      Quant / Vol
      risk profile
      High
      Volatility 47%
      annualized · 1-yr
      Max drawdown −16%
      past year
      ATR 2.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Sep 30, 2025
      Revenue run rate · not later than 2027 $4B
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2023
      Cash in the operating budget · 2023 up to 50%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      1 · 5 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −0% Neutral
      Price vs 50-day avg
      −3% Neutral
      RSI (14)
      47 Neutral
      MACD trend
      Negative Bearish
      52-week position
      73% Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $535 › 200d $520 — 50d above 200d
      Institutional flow Accumulating
      +4% holders QoQ · +115 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      5.42% of float · ▲ +11.2% MoM · 5.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      871 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $305 Now $518 · 73% Range high $597
      vs 200-day avg 0% vs 50-day avg -3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      UTHR
      UNITED THERAPEUTICS Corp
      this stock
      		$22.23B +6.4% +2.4% 18.6 5.4%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $57.75B +15.8% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $50.24B +4.0% — — 0.0%
      HLN
      Haleon plc
      		 $43.41B -3.9% — — 0.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      871
      % held
      101.7%
      Net QoQ
      +3.7M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      712
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      2.3M
      Days to cover
      5.5d
      Change
      +233.9K sh
      View
      Short Volume
      Short vol %
      61%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      22
      Value
      $11.7K
      As of
      Jul 16, 2026
      View
      Off-Exchange
      Off-exchange %
      40.8%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Lisa McClain
      Amount
      $1.0K–$15.0K
      Traded
      Oct 31, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $3.2B
      Net income (FY)
      $1.3B
      EPS diluted
      $27.86
      View
      Buybacks
      Authorized
      $2.0B
      Remaining
      $500.0M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 5, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $4.3M
      Shares
      8.3K
      Filed
      Aug 6, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      UTHR +0.5% -3.3% -3.2% +0.1% +6.4%
      SPY -0.4% +2.6% +10.7% +2.7% +12.5%
      vs SPY +0.9% -5.8% -13.9% -2.6% -6.2%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $2.00B
      Spent (derived)
      $1.50B
      Remaining
      $500.00M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1082554 CUSIP 91307C102 13F (30d) 789 filings 769 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)